CAMBRIDGE, MA, USA I March 11, 2025 I Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase ...

BIIB's TRANSCEND phase III study on felzartamab in adult kidney transplant recipients diagnosed with late AMR is set to enroll approximately 120 patients.

2-Year U.S. Treasury Note Continuous Contract $103.598 0.016 0.02% 5-Year U.S. Treasury Note Continuous Contract $108.000 0.094 0.09% 10-Year U.S. Treasury Note Continuous Contract $110.969 0.125 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants ...

Rights Jan 28, 2008 Feb 04, 2008 Jan 14, 2008 Rights ratio: 1 share for every 5 held at a price of Rs 1590.0 Rights Nov 26, 1993 Dec 24, 1993 Nov 26, 1993 Rights ratio: 3 share for every 5 held at a ...